Abstract 3579: Impaired flow-mediated vasodilatation is associated with increased left ventricular mass in a multi-ethnic population. The Northern Manhattan Study.
Introduction: Increased left ventricular mass (LVM) and endothelial dysfunction are important factors for cardiovascular mortality and morbidity. However, it is not clear whether endothelial dysfunction is one of the determinants of increased LVM. Aim: We tested the hypothesis that impaired flow-mediated vasodilatation (FMD) is a determinant of increased LVM in a population-based multi-ethnic cohort.
Methods: As a part of the Northern Manhattan Study (NOMAS), we performed two-dimensional echocardiography and flow-mediated vasodilatation
(FMD) assessment during reactive hyperemia by high-resolution ultrasonography in 867 community participants who were free from stroke or myocardial infarction. LVM was calculated according to an established method. Left ventricular hypertrophy (LVH) was defined by the upper quartile of LVM. Multivariable models were used to test the association of FMD with LVM (continuous and categorical) after adjusting for age, gender, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, diabetes, smoking, and race/ ethnicity.
Results: The mean age was 67±9 years; 43% male; 15% white, 18% black, and 67% Hispanics. The mean FMD was 5.8±3.8 % in whites, 5.7±3.7 % in Hispanics, and 5.7±4.0 % in blacks. In multiple linear regression analyses, FMD was inversely correlated with LVM (β= −1.69, SE=0.50 p<0.01), independent of covariates. In a multiple logistic regression model (Table⇓) , each 1% decrease in FMD increases risk of LVH by 6% [OR 1.06 (95% CI=1.04 –1.09, p<0.01)]. Race/ethnicity was not a significant modifier of the association of FMD with LVM in any analyses.
Conclusion: Impaired FMD was associated with LVH, independent of other factors associated with increased LVM. Endothelial function should be taken considered in patients with LVH in addition to conventional risk factors.